Novartis snaps up rare disease biotech DTx Pharma in $1bn deal
The acquisition adds an siRNA delivery platform to Novartis’s armament and a potential first-in-class treatment for Charcot-Marie-Tooth Disease.
The acquisition adds an siRNA delivery platform to Novartis’s armament and a potential first-in-class treatment for Charcot-Marie-Tooth Disease.
What's Your Reaction?
